nach oben

Documenta Ophthalmologica

Erschienen in:

01.02.2010 | Review Article

The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50/10 OIR model

verfasst von: M. Elizabeth Hartnett

Erschienen in: Documenta Ophthalmologica | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study is to determine growth factor expression and activation of signaling pathways associated with intravitreous neovascularization and peripheral avascular retina using a model of retinopathy of prematurity (ROP) relevant to today with oxygen monitoring in neonatal units. Studies using 50/10 oxygen-induced retinopathy (OIR) and 50/10 OIR+SO models were reviewed. Repeated fluctuations in oxygen increased retinal vascular endothelial growth factor (VEGF) even while peripheral avascular retina persisted and prior to the development of intravitreous neovascularization. Repeated fluctuations in oxygen increased VEGF₁₆₄ expression but not VEGF₁₂₀. Neutralizing VEGF bioactivity significantly reduced intravitreous neovascularization and arteriolar tortuosity without interfering with ongoing retinal vascularization. Repeated oxygen fluctuations led to retinal hypoxia and increased reactive oxygen species (ROS). Inhibiting ROS with NADPH oxidase inhibitor, apocynin, reduced avascular retina by interfering with apoptosis. Supplemental oxygen reduced retinal VEGF concentration and exacerbated NADPH oxidase activation to contribute to intravitreous neovascularization through activation of the JAK/STAT pathway. Oxygen stresses relevant to those experienced by preterm infants today trigger signaling of different pathways to cause avascular retina and intravitreous neovascularization. Increased signaling of VEGF appears important to the development of both avascular retina and intravitreous neovascularization.

Penn JS, Henry MM, Tolman BL (1994) Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res 36:724–731CrossRefPubMed

Patz A, Eastham A, Higginbotham DH, Kleh T (1953) Oxygen studies in retrolental fibroplasia. Am J Ophthalmol 36:1511–1522PubMed

Patz A (1965) The effect of oxygen on immature retinal vessels [Review] [23 refs]. Invest Ophthalmol 4:988–999

Berkowitz BA, Zhang W (2000) Significant reduction of the panretinal oxygenation response after 28% supplemental oxygen recovery in experimental ROP. Invest Ophthalmol Vis Sci 41:1925–1931PubMed

McColm JR, Hartnett ME (2005) Retinopathy of prematurity: current understanding based on clinical trials and animal models. In: Hartnett MEE, Trese MT, Capone A Jr, Steidl SM, Keats BK (eds) Pediatric retinal diseases: medical and surgical approaches. Lippincot Williams & Wilkins, Philadelphia

Cryotherapy for Retinopathy of Prematurity Cooperative Group (2001) Multicenter trial of cryotherapy for retinopathy of prematurity ophthalmological outcomes at 10 years. Arch Ophthalmol 119:1110–1118

Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684–1694CrossRefPubMed

Flynn JT (1987) Retinopathy of prematurity. Ped Clin N Am 34:1487–1516

Cryotherapy for Retinopathy of Prematurity Cooperative Group (2002) Multicenter trial of cryotherapy for retinopathy of prematurity: natural history ROP: ocular outcome at 5(1/2) years in premature infants with birth weights less than 1251 g. Arch Ophthalmol 120:595–599

10.

Ernest JT, Goldstick TK (1984) Retinal oxygen tension and oxygen reactivity in retinopathy of prematurity in kittens. Invest Ophthalmol Vis Sci 25:1129–1134PubMed

11.

Saito Y, Uppal A, Byfield G, Budd S, Hartnett ME (2008) Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model. Invest Ophthalmol Vis Sci 49:1591–1598CrossRefPubMed

12.

Terry TL (1942) Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens: (1) preliminary report. Am J Ophthalmol 25:203–204

13.

Wang S, Sorenson CM, Sheibani N (2005) Attenuation of retinal vascular development and neovascularization during oxygen-induced ischemic retinopathy in Bcl-2^−/− mice. Dev Biol 279:205–219CrossRefPubMed

14.

Shih SC, Ju M, Liu N, Smith LEH (2003) Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest 112:50–57PubMed

15.

Alon T, Hemo I, Itin A, Peer J, Stone J, Keshet E (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1:1024–1028CrossRefPubMed

16.

Chang KH, Chan-Ling T, McFarland EL, Afzal A, Pan H, Baxter LC, Shaw LC, Caballero S, Sengupta N, Calzi SL, Sullivan SM, Grant MB (2007) IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc Natl Acad Sci USA 104:10595–10600CrossRefPubMed

17.

Lofqvist C, Chen J, Connor KM, Smith ACH, Aderman CM, Liu N, Pintar JE, Ludwig T, Hellstrom A, Smith LEH (2007) From the cover: IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci USA 104:10589–10594CrossRefPubMed

18.

Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, Hong S, Pravda EA, Majchrzak S, Carper D, Hellstrom A, Kang JX, Chew EY, Salem N, Serhan CN, Smith LEH (2007) Increased dietary intake of [omega]-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 13:868–873CrossRefPubMed

19.

Neu J, Afzal A, Pan H, Gallego E, Calzi SL, Caballero S, Spoerri PE, Shaw LC, Grant MB (2006) The dipeptide Arg-Gln inhibits retinal neovascularization in the mouse model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 47:3151–3155CrossRefPubMed

20.

Penn JS (1992) Oxygen-induced retinopathy in the rat. Vitamins C and E as potential therapies. Invest Ophthalmol Vis Sci 33:1836–1845PubMed

21.

Penn JS, Tolman BL, Bullard LE (1997) Effect of a water-soluble vitamin E analog, Trolox C, on retinal vascular development in an animal model of retinopathy of prematurity. Free Radic Biol Med 22:977–984CrossRefPubMed

22.

Niesman MR, Johnson KA, Penn JS (1997) Therapeutic effect of liposomal superoxide dismutase in an animal model of retinopathy of prematurity. Neurochem Res 22:597–605CrossRefPubMed

23.

Saito Y, Geisen P, Uppal A, Hartnett ME (2007) Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity. Mol Vis 13:840–853PubMed

24.

Ashton N, Cook C (1954) Direct observation of the effect of oxygen on developing vessels: preliminary report. Br J Ophthalmol 38:433–440CrossRefPubMed

25.

Michaelson IC (1948) The mode of development of the vascular system of the retina. With some observations on its significance for certain retinal diseases. Trans Ophthal Soc UK 68:137–180

26.

Cunningham S, Fleck BW, Elton RA, Mclntosh N (1995) Transcutaneous oxygen levels in retinopathy of prematurity. Lancet 346:1464–1465CrossRefPubMed

27.

McColm JR, Cunningham S, Wade J, Sedowofia K, Gellen B, Sharma T, McIntosh N, Fleck BW (2004) Hypoxic oxygen fluctuations produce less severe retinopathy than hyperoxic fluctuations in a rat model of retinopathy of prematurity. Pediatr Res 55:107–113CrossRefPubMed

28.

Saito Y, Omoto T, Cho Y, Hatsukawa Y, Fujimura M, Takeuchi T (1993) The progression of retinopathy of prematurity and fluctuation in blood gas tension. Graefes Arch Clin Exp Ophthalmol 231:151–156CrossRefPubMed

29.

Chow LC, Wright KW, Sola A (2003) Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? Pediatrics 111:339–345CrossRefPubMed

30.

Wedrychowicz A, Dziatkowiak H, Nazim J, Sztefko K (2005) Insulin-like growth factor-1 and its binding proteins, IGFBP-1 and IGFBP-3, in adolescents with type-1 diabetes mellitus and microalbuminuria. Horm Res 63(5):245–299CrossRefPubMed

31.

Tin W, Milligan DWA, Pennefather PM, Hey E (2001) Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonat Ed 84:106–110CrossRef

32.

Werdich XQ, McCollum GW, Rajaratnam VS, Penn JS (2004) Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy. Exp Eye Res 79:623–630CrossRefPubMed

33.

McColm JR, Cunningham S, Yerden R (1999) A computer controlled system to simulate the small, rapid oxygen fluctuations experienced by preterm infants developing retinopathy of prematurity. Scott Med J 44(1):28–29

34.

Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LEH (1995) Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 92:905–909CrossRefPubMed

35.

Penn JS, Henry MM, Wall PT, Tolman BL (1995) The range of PaO2 variation determines the severity of oxygen induced retinopathy in newborn rats. Invest Ophthalmol Vis Sci 36:2063–2070PubMed

36.

Phelps DL (1988) Reduced severity of oxygen-induced retinopathy in kittens recovered in 28% oxygen. Pediatr Res 24:106–109CrossRefPubMed

37.

Gu X, Samuel S, El shabrawey M, Caldwell RB, Bartoli M, Marcus DM, Brooks SE (2002) Effects of sustained hyperoxia on revascularization in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci 43:496–502PubMed

38.

The STOP-ROP Multicenter Study Group (2000) Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 105:295–310CrossRef

39.

Wallace DK, Veness-Meehan KA, Miller WC (2007) Incidence of severe retinopathy of prematurity before and after a modest reduction in target oxygen saturation levels. J AAPOS 11:170–174CrossRefPubMed

40.

Vanderveen DK, Mansfield TA, Eichenwald EC (2006) Lower oxygen saturation alarm limits decrease the severity of retinopathy of prematurity. J AAPOS 10:445–448CrossRefPubMed

41.

Liu K, Akula JD, Falk C, Hansen RM, Fulton AB (2006) The retinal vasculature and function of the neural retina in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 47:2639–2647CrossRefPubMed

42.

Hartnett ME, Martiniuk DJ, Byfield GE, Geisen P, Zeng G, Bautch VL (2008) Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in rat model of ROP: relevance to plus disease. Invest Ophthalmol Vis Sci 49(7):3107–3114. Epub 2008 Mar 31

43.

McColm JR, Geisen P, Hartnett ME (2004) VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis 10:512–520PubMed

44.

Werdich XQ, Penn JS (2006) Specific involvement of Src family kinase activation in the pathogenesis of retinal neovascularization. Invest Ophthalmol Vis Sci 47:5047–5056CrossRefPubMed

45.

Aylward SR, Bullitt E (2002) Initialization, noise, singularities, and scale in height ridge traversal for tubular object centerline extraction. IEEE Trans Med Imaging 21:61–75CrossRefPubMed

46.

Chan-Ling T, Gock B, Stone J (1995) The effect of oxygen on vasoformative cell division: evidence that ‘physiological hypoxia’ is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci 36:1201–1214PubMed

47.

Stone J, Itin A, Alon T, Peer J, Gnessin H, Chan-Ling T, Keshet E (1995) Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 15:4738–4747PubMed

48.

Saint-Geniez M, Maldonado AE, D’Amore PA (2006) VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci 47:3135–3142CrossRefPubMed

49.

Maharaj ASR, Saint-Geniez M, Maldonado AE, D’Amore PA (2006) Vascular endothelial growth factor localization in the adult. Am J Pathol 168:639–648CrossRefPubMed

50.

Robinson GS, Aiello LP (1998) Angiogenic factors in diabetic ocular disease: mechanisms of today, therapies for tomorrow. Int Ophthalmol Clin 38:89–102PubMed

51.

Adamis AP, Miller JW, Bernal MT, D’Amico DJ, Folkman J, Yeo TK, Yeo KT (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445–450PubMed

52.

Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285:245–248CrossRefPubMed

53.

Duh EJ, Yang HS, Suzuma I, Miyagi M, Youngman E, Mori K, Katai M, Yan L, Suzuma K, West K, Pearlman J, Crabb JW, Aiello LP, Campochiaro PA, Zack DJ (2002) Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 43:821–829PubMed

54.

Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA (2002) Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 43:2428–2434PubMed

55.

Gao G, Li Y, Gee S, Dudley A, Fant J, Crosson C, Ma J (2002) Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor. A possible mechanism for the anti-angiogenesis activity of plasminogen kringle 5. J Biol Chem 277:9492–9497CrossRefPubMed

56.

Shima DT, Kuroki M, Deutsch U, Ng YS, Adamis AP, D’Amore PA (1996) The mouse gene for vascular endothelial growth factor. J Biol Chem 271:3877–3883CrossRefPubMed

57.

Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947–11954PubMed

58.

Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, Hida T, Oguchi Y, Ambati J, Miller JW, Gragoudas ES, Ng YS, D’Amore PA, Shima DT, Adamis AP (2003) VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 198:483–489CrossRefPubMed

59.

Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, Moore T, Amano S, Horikawa Y, Dartt D, Golding M, Shima DT, Adamis AP (2004) VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci 45:368–374CrossRefPubMed

60.

Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169:681–691CrossRefPubMed

61.

Stalmans I, Ng YS, Rohan R, Fruttiger M, Bouche A, Yuce A, Fujisawa H, Hermans B, Shani M, Jansen S, Hicklin D, Anderson DJ, Gardiner TA, Hammes HP, Moons L, Dewerchin M, Collen D, Carmeliet P, D’Amore PA (2002) Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest 109:327–336PubMed

62.

Carmeliet P, Ng YS, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, Ehler E, Kakkar VV, Stalmans I, Mattot V, Perriard J-C, Dewerchin M, Flameng W, Nagy A, Lupu F, Moons L, Collen D, D’Amore PA, Shima DT (1999) Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 5:495–501CrossRefPubMed

63.

Ng YS, Rohan R, Sunday ME, Demello DE, D’Amore PA (2001) Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 220:112–121CrossRefPubMed

64.

Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, Betsholtz C, Shima DT (2002) Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 16:2684–2698CrossRefPubMed

65.

Hutchings H, Ortega N, Plouet J (2003) Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. FASEB J 17:1520–1522PubMed

66.

Pierce E, Foley E, Lois EH (1996) Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 114:1219–1228PubMed

67.

Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161:1163–1177CrossRefPubMed

68.

Geisen P, Peterson LJ, Martiniuk D, Uppal A, Saito Y, Hartnett ME (2008) Neutralizing antibody to VEGF reduces intravitreous neovascularization and does not interfere with vascularization of avascular retina in an ROP model. Mol Vis 14:345–357PubMed

69.

Hughes S, Gardiner T, Baxter L, Chan-Ling T (2007) Changes in pericytes and smooth muscle cells in the kitten model of retinopathy of prematurity: implications for plus disease. Invest Ophthalmol Vis Sci 48:1368–1379CrossRefPubMed

70.

Holland D, Saunders R, Kagemann L, Bluestein E, Hutchinson A, Corson D, Harris A (1999) Color Doppler imaging of the central retinal artery in premature infants undergoing examination for retinopathy of prematurity. J AAPOS 3:194–198CrossRefPubMed

71.

Niwald A, Gralek M (2006) Evaluation of blood flow in the ophthalmic artery and central retinal artery in children with retinopathy of prematurity. Klin Oczna 108:32–35PubMed

72.

Brooks SE, Gu X, Samuel S, Marcus DM, Bartoli M, Huang PL, Caldwell RB (2001) Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice. Invest Ophthalmol Vis Sci 42:222–228PubMed

73.

Zeng G, Taylor SM, McColm JR, Kappas NC, Kearney JB, Williams LH, Hartnett ME, Bautch VL (2007) Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation. Blood 109:1345–1352CrossRefPubMed

74.

Katz ML, Robison WG Jr (1988) Autoxidative damage to the retina: potential role in retinopathy of prematurity. Birth Defects 24:237–248PubMed

75.

Penn JS (1990) Oxygen-induced retinopathy in the rat: possible contribution of peroxidation reactions. Doc Ophthalmol 74:179–186CrossRefPubMed

76.

Phelps DL, Rosenbaum AL (1979) Observations of vitamin E in experimental oxygen-induced retinopathy. Ophthalmology 86:1741–1748PubMed

77.

Penn JS, Tolman BL, Lowery LA (1993) Variable oxygen exposure causes preretinal neovascularisation in the newborn rat. Invest Ophthalmol Vis Sci 34:576–585PubMed

78.

Ushio-Fukai M (2006) Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc Res 71:226–235CrossRefPubMed

79.

Jay Forman H, Torres M (2001) Redox signaling in macrophages. Mol Aspects Med 22:189–216CrossRef

80.

Al Shabrawey M, Bartoli M, El Remessy AB, Platt DH, Matragoon S, Behzadian MA, Caldwell RW, Caldwell RB (2005) Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol 167:599–607PubMed

81.

Raju TNK, Langenberg P, Bhutani V, Quinn GE (1997) Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials. J Pediatr 131:844–850CrossRefPubMed

82.

Kramerov AA, Saghizadeh M, Pan H, Kabosova A, Montenarh M, Ahmed K, Penn JS, Chan CK, Hinton DR, Grant MB, Ljubimov AV (2006) Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina. Am J Pathol 168:1722–1736CrossRefPubMed

83.

Dorrell MI, Aguilar E, Scheppke L, Barnett FH, Friedlander M (2007) Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci USA 104:967–972CrossRefPubMed

84.

Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP, Shima DT (2006) Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168:2036–2053CrossRefPubMed

85.

Sears JE, Pietz J, Sonnie C, Dolcini D, Hoppe G (2009) A change in oxygen supplementation can decrease the incidence of retinopathy of prematurity. Ophthalmology 116:513–518CrossRefPubMed

86.

Byfield GE, Budd S, Hartnett ME (2009) Supplemental oxygen can cause intravitreous neovascularization through JAK/STAT pathways in a model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. Epub (Mar 5), PMID: 19264880

87.

Ushio-Fukai M, Alexander RW (2004) Reactive oxygen species as mediators of angiogenesis signaling. Role of NAD(P)H oxidase. Mol Cell Biochem V264:85–97CrossRef

88.

Ushio-Fukai M (2007) VEGF signaling through NADPH oxidase-derived ROS. Antioxid Redox Signal 9:731–739CrossRefPubMed

89.

Liu T, Castro S, Brasier AR, Jamaluddin M, Garofalo RP, Casola A (2004) Reactive oxygen species mediate virus-induced STAT activation: role of tyrosine phosphatases. J Biol Chem 279:2461–2469CrossRefPubMed

90.

Lee YJ, Heo JS, Suh HN, Lee MY, Han HJ (2007) Interleukin-6 stimulates {alpha}-MG uptake in renal proximal tubule cells: involvement of STAT3, PI3K/Akt, MAPKs, and NF-{kappa}B. Am J Physiol Renal Physiol 293:F1036–F1046CrossRefPubMed

91.

Banes AK, Shaw S, Jenkins JA, Redd H, Amiri F, Pollock DM, Marrero MB (2004) Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am J Physiol Renal Physiol 286:F653–F659CrossRefPubMed

92.

Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LEH (1996) Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 93:4851–4856CrossRefPubMed

93.

Akula JD, Hansen RM, Martinez-Perez ME, Fulton AB (2007) Rod photoreceptor function predicts blood vessel abnormality in retinopathy of prematurity. Invest Ophthalmol Vis Sci 48:4351–4359CrossRefPubMed

94.

Berkowitz BA, Roberts R, Penn JS, Gradianu M (2007) High-resolution manganese-enhanced MRI of experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci 48:4733–4740CrossRefPubMed

95.

Cringle SJ, Yu PK, Su EN, Yu DY (2006) Oxygen distribution and consumption in the developing rat retina. Invest Ophthalmol Vis Sci 47:4072–4076CrossRefPubMed

Titel: The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50/10 OIR model
verfasst von: M. Elizabeth Hartnett
Publikationsdatum: 01.02.2010
Verlag: Springer-Verlag
Erschienen in: Documenta Ophthalmologica / Ausgabe 1/2010
Print ISSN: 0012-4486
Elektronische ISSN: 1573-2622
DOI: https://doi.org/10.1007/s10633-009-9181-x

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50/10 OIR model

Abstract

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

The significance of neuronal and glial cell changes in the rat retina during oxygen-induced retinopathy

Oxygen supply and consumption in the retina: implications for studies of retinopathy of prematurity

Hereditary influences in oxygen-induced retinopathy in the rat

ISCEV standard for clinical visual evoked potentials (2009 update)

The development of the rat model of retinopathy of prematurity

Understanding ischemic retinopathies: emerging concepts from oxygen-induced retinopathy

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde